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ABSTRACT
Objective: Compare the percentage of bone neoformation 
promoted by autologous bone grafting and three kinds of re-
placement materials with different characteristics in rats’ 
femoral holes. Methods: Two holes measuring 5.4 x 2.7mm, 
were produced on each femur (right and left) of 14 isogenic 
Wistar rats. Each of the four defects produced was filled by 
autologous bone or by one of three tested materials – hy-
droxyapatite (HA), Genphos® (HA+ ß-TCP) and GenMix® (a 
combined bovine bone graft). In the end of the 6-week (n = 6) 
and 12-week (n = 8) periods, the animals were sacrificed. The 
sections (stained with Picro-Sirius) were assessed by optical 
microscopy and specific software. Results: The groups with 
autologous bone were shown to be significantly superior to the 
others at both assessed times, showing a mean bone formation 
rate ± SD of 90.6 ± 10.8% in six weeks, and 98 ± 9.2% in 
12 weeks (p > 0.0001 for both assessed times). In six weeks, 
the results for the other groups were the following: Genphos®, 
46 ± 7.1%; HA, 43.1 ± 8.4%; and GenMix®, 57.3 ± 4.5%. In 12 
weeks: Genphos®, 47.8 ± 11.1%; HA, 39.9 ± 5.4%; GenMix®, 
59.7 ± 4.8%, significant (p = 0.007). Conclusions: In both as-
sessed times, the three bone replacement materials tested in the 
study showed to be inferior to autologous bone graft for bone 
neoformation percentage. 
Keywords – Bone regeneration; Bone transplantation; Durapa-
tite; Calcium phosphates; Transplantation, heterotopic; Trans-
plantation, autologous; Biocompatible materials; Rats, Wistar
INTRODUCTION
There are numerous accidents or diseases in which 
there is loss of bone tissue that needs to be replaced (in 
the U.S. alone, there are an estimated about 500,000 
bone graft procedures per year)(1). To the present day, 
the treatment of choice to recover from this type of 
injury is the autogenous bone graft (gold standard), an 
established and very effective surgical procedure that is 
far from perfect. Among its disadvantages that could be 
cited are its difficulty of acceptance by patients (because 
it is necessary to remove bone from another area), the 
volume and shape of the limited donor sites, the defect 
generated during graft extraction, and postoperative 
state of the donor area, which usually presents more 
complications than the recipient area(1-6). Because of 
these limitations, there is a constant search for a grafting 
material that can replace autogenous bone, with the same 
quality of treatment, but with fewer drawbacks. It seems 
that an ideal substitute has yet to be created(6-8).
A bone substitute with ideal characteristics should 
have physicochemical properties similar to bone to 
facilitate bone regeneration, should combine osteo-
inductive and osteoconductive properties, and should 
be biocompatible and resorbable, to be completely 
replaced by bone(8,9).
The objective of this study was to compare the per-
centage of new bone formation after grafting between 
the current gold standard (autogenous bone graft) and 
three bone substitutes with different characteristics to 
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see if any of these would be able to replace the standard 
without significant loss of quality.
METHODS
We used 14 young adult male isogenic Wistar (Rattus 
norvegicus) rats of the Kyoto strain between two and 
four months old, weighing between 220 and 300 grams, 
from the Microsurgery and Medical Skills Laboratory at 
PUC/RS, where all surgical procedures were performed. 
The specimens were randomly assigned into two 
experimental groups which received the same treatment 
but were sacrificed and analyzed at different times, at six 
weeks (n = 6) and 12 weeks (n = 8).
In each treated specimen, anesthesia was 
administered intraperitoneally with a solution 
consisting of 0.2 ml of chlorpromazine hydrochloride 
(5 mg/ml) + 0.8 ml of ketamine (50 mg/ml), at a dose 
of 0.3 ml of solution/100 grams of rat body weight 
(which is equivalent to 0.3 mg chlorpromazine + 12 
mg of ketamine/100 g of rat body weight). Trichotomy 
was performed in the area of surgical access over 
both femurs (left and right). Maintenance doses of 
anesthetic were prepared to be administered in the 
course of surgery as needed (half the initial dose).
A longitudinal incision of approximately 4 cm was 
made parallel and anterior to the axis of each femur, 
one at a time. The anterior area of each femur was 
exposed with the delicate dissection of muscle and 
periosteum. With the aid of a BLM 600 Plus electric 
motor against a 1 x 1 dental angle, two 5.4 mm cavities 
were made using a 2.7 mm trephine drill in two 
adjacent cavities, 2.7 mm x 2 = 5.4 mm. To prepare 
these cavities, a constant torque was set to 45N, speed 
was set at 45,000rpm, and copious irrigation (70% 
– adjustment of the electric motor) with saline for 
viability of bone regeneration.
After drilling, the bone fragments were carefully 
removed (Figure 1) and stored in sterile dappen 
dishes. Later, these will be used as autogenous bone 
to be grafted (after being particulated with dental 
minialveolotomy) in one of the cavities. Each of the 
remaining cavities was filled with one of the bone 
substitute materials to be tested: hydroxyapatite (HA) 
(Bionnovation, Inc., Brazil), (HA + ß-TCP) – Genphos® 
(Baumer, Inc., Brazil) and (a bovine composite bone 
graft) – GenMix® (Baumer, Inc., Brazil). The distribution 
of the position of each material in the cavities of 
the femurs underwent clockwise rotation for the 
Figure 1 – Photograph showing the perforations made and the 
beginning of bone removal, which will be used as a source for 
autogenous grafting
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standardization of grafted areas with each material.
The periosteal, plane, and skin sutures were performed 
with mononylon 4-0 (Ethilon®, Johnson & Johnson, Bra-
zil). The rats were kept in individual cages after surgery.
For the sacrification of animals at the determined 
times, the previously mentioned dose of anesthesia was 
administered; later, an 100 mg/kg intracardiac overdose 
of pentobarbital sodium was applied to the previously 
anesthetized rat.
After the euthanasia of the animals, there was a deli-
cate removal of the right and left femurs (Figure 2), 
which were immediately placed in formalin 10% for 
three days. The femurs were then sectioned with the 
help of a dental carborundum disk, the same electric 
motor used in other surgeries, and the 1 x 1 straight 
piece. About 0.5 to 1 mm of healthy bone was sectioned 
beyond the grafted area on both sides of the treated area.
Figure 2 – Photograph showing the appearance of the four 
groups tested after 12 weeks: A) Genmix®, B) Genphos®, C) HA 
(Bionnovation), D) Autologous. Note the difficulty of locating the 
area of the autogenous graft (D)
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Figure 4 – Image showing the characteristics of an area treated 
with Genphos® after 12 weeks, stained with picrosirius, at 50x 
magnification. The arrow shows the normal neoformed bone 
Figure 5 – Image showing the characteristics of an area treated 
with hydroxyapatite (HA) after 12 weeks, stained with picrosirius, 
at 50x magnification. The arrow shows the normal neoformed bone 
All treatments were separated according to the type 
of graft performed; slow decalcification was performed 
with formic acid at a 30% concentration in an oven at 
37°C, changed every three days for a period of two 
weeks. After complete decalcification, specimens were 
embedded in paraffin for microtome cutting and pro-
duction of histological slides.
After discarding the first millimeter of each region 
tested, 10 histological slides were prepared with two to 
 !"#$%&'($)*+,$- $+.#$ #(*/$#0).1$/#2#0+!34$+.#$2/-)#-
dure for every 1 mm of the region analyzed.
After 24 hours in an oven at 60°C, the slides were 
placed in a solution of 1% picrosirius for an hour, then 
washed in running water for 20 minutes. When dried, 
the slides were examined and cataloged to choose the 
areas to be photographed and analyzed.
All groups were examined with standard light mi-
croscopy at 5x magnification. When capturing images 
with the aid of a Cool Snap Pro camera, a magnification 
similar to a 10x objective lens is produced. Thus, the 
resulting images are magnified 50x.
For the analysis, at least three different areas were 
stipulated with a minimum of 1 mm of space between 
them. In the region adjacent to the lesion, an area on the 
same slide with similar length and width as each treated 
area was selected as a 100% bone neoformation control.
The captured images were analyzed with Image 
Pro Plus, version 4.5.1, used by the Department of 
Pathology, Hospital São Lucas, PUC/RS.
With help of this program, the area corresponding to 
the bone in each captured image was selected (Figures 
3, 4, 5, and 6), and a specific “mask” was applied. 
This area, when measured with the program described 
above, generates a count of the number of matching 
pixels. The percentage of new bone formation in the 
treated area was calculated by comparing the bone in 
this (treated) area to the bone present in the adjacent 
untreated (control) area, which was set as 100% of 
neoformation (ideal).
Data are presented as means and standard deviations. 
To compare new bone formation between the groups, 
we used analysis of variance (ANOVA) followed by 
Tukey post hoc test. The comparison of the times was 
performed by Student’s t-test. The level of significance 
50,$,#+$0+$6$7$&8&%8$90+0$5#/#$030:;<#=$5!+.$>?>>8
The research protocol of the experiment was 
submitted to the Research Ethics Committee of the 
Pontifícia Universidade Católica do Rio Grande do 
Sul, with no changes or modifications made to the 
proposed procedures.
Figure 3 – Image showing the characteristics of an area treated 
with autogenous bone after 12 weeks, stained with picrosirius, at 
50x magnification. The arrow shows the normal neoformed bone 
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Figure 6 – Image showing the characteristics of an area treated 
with Genmix® bone after 12 weeks, stained with picrosirius, at 
50x magnification. The arrow shows the normal neoformed bone 
Table 1 – Distribution of animals per group, losses, and treatment 
areas analyzed
Group Treated areas
Number and causes of 
losses
Analyzed treatment 
areas
6 semanas
24 
(6 x 4)
3 femur fractures; 2 
decalcification and slide 
preparation problems.
4 Autogenous
5 Genphos®
4 HA
4 GenMix®
17 TOTAL
12 semanas
32
(8 x 4)
5 femur fractures; 4 
decalcification and slide 
preparation problems.
5 Autogenous
5 Genphos®
5 HA
5 GenMix®
20 TOTAL
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RESULTS
None of the rats used died after the procedure 
or during the experiment. Despite all the animals 
appearing healthy – none showed restrictions in their 
movement – dissection of the fractured femurs revealed 
three fractures in the six week group and five fractures 
in the 12 week group (Table 1), probably caused by 
the large size of the cavities made and the fact that the 
lesions were performed in both femurs.
The remaining losses were due to failures in 
decalcification or in preparation of the slides, thus 
having no means by which to be analyzed, and were 
therefore excluded.
The mean values of bone neoformation and their 
respective standard deviations are shown in Table 2 
and Figure 7.
DISCUSSION
There are currently numerous bone substitutes on 
the market (HA, ß-TCP, bioglass) with many different 
features to try to replace autogenous bone. The 
companies that make them use strong marketing to try to 
convince the consumer that this or that produces better 
results and that, as if it were obvious, their product is of 
a superior quality to those of other companies.
Good studies on many of these materials are still 
scarce and inconclusive. Normally, only two or three 
different materials are compared and rare are the 
experiments that compare several groups of substitutes 
with the current gold standard, the autogenous bone graft.
In addition to autogenous bone, we tested a ß-TCP 
+ HA (Genphos®) and a resorbable HA (Bionnovation) 
Table 2 – Variation in mean ± SD for the rate of bone neoforma-
tion in the two periods analyzed
Time Type of graft n Mean Standard deviation
6 weeks
Autogenous
Genphos®
Resorbable HA
GenMix®
Total
4
5
4
4
17
90.5
46.0
43.1
57.3
10.8
7.1
8.4
4.5
12 weeks
Autogenous
Genphos®
Resorbable HA
GenMix®
Total
5
5
5
5
20
98.0
47.8
39.9
59.7
9.1
11.1
5.4
4.8
Figure 7 – Graph of means and standard deviations represent-
ing the values of new bone formation between the study groups
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Figure 8 – X-ray showing radiological findings after 12 weeks: A) 
Autogenous, B) HA (Bionnovation), C) GenMix®, D) Genphos®
– two alloplastic grafts that would have only 
osteoconductive characteristics – and GenMix®, an 
example of a xenograft, which could theoretically have 
osteoconductive characteristics, because of its inorganic 
matrix, and osteoinductive characteristics, because of 
its organic matrix, which would, on the other hand, 
theoretically decrease its carrying capacity(9).
The allografts derived from synthetic HA (and its 
variations) are highly biocompatible and appear to have 
biological responses similar to those of bone(9). The 
results in the literature depend on various formulations 
and are still inconclusive as to the quantity and quality 
of neoformed bone(6-8,10-14). By changing its composition 
(such as the addition of ß-TCP) and its method of 
production, the speed of resorption of HA, which 
naturally occurs very slowly, could be modified(8,9).
Xenografts have the great advantage of having the 
greatest similarity with natural bone – when analyzing 
its inorganic component (varying in crystallinity and 
morphology according to the method of preparation)
(15) – and could, in theory, retain osteoinductive 
features in their inorganic component(6,9), which would 
supposedly have greater immunogenic potential(3). 
With the association of the two components, GenMix® 
would either combine the benefits of the two or 
would have its osteoinductive capacity and/or support 
affected by this mixture(6,10,13,16).
Human and rat osteoclasts show a similar pattern 
of resorption. Thus, the animal model used in this 
study would be valid for the study of the resorption 
of bone substitutes(17).
At all times analyzed, the area treated with 
autogenous bone was even difficult to locate because 
of its excellent regeneration (Figure 2); in all other 
materials the presence of the inorganic portion of their 
granules is quite noticeable, and there is none that has 
been completely reabsorbed. These findings can be 
confirmed by the histological results (Figures 3, 4, 5, 
and 6), and may also be seen on x-ray images (Figure 8) 
taken after dissection of the femurs.
There were no areas with complete graft failure, and 
the materials served to maintain the relative volume 
of the treated area. The question to be explored should 
really be about the amount of normal bone present in 
these areas and the quality of bone resulting from this 
treatment. In autogenous bone, on the other hand, there 
was even a thickening in some areas in relation to the 
control image, which explains why some values are 
above 100% in the statistics.
In conclusion, at both times analyzed (six and 12 
weeks) and the model tested, autogenous bone graft 
showed a mean percentage of new bone formation far 
Tabela 3 – Statistics
Dependent variable: mperc Tukey HSD
Time
(I) 
group
(J) 
group
Mean 
difference 
(I-J)
Standard 
deviation
Sig.
95% confidence interval
Maximum 
value
Minimum 
value
6 1 2
3
4
44.54885*
47.37370*
33.22033*
5.37275
5.66338
5.66338
.000
.000
.000
28.7792
30.7511
16.5977
60.3185
63.9963
49.8430
2 1
3
4
–44.54885*
2.82485
–11.32852
5.37275
5.37275
5.37275
.000
.951
.201
–60.3185
–12.9448
–27.0981
–28.7792
18.5945
4.4411
3 1
2
4
–47.37370*
–2.82485
–14.15337
5.66338
5.37275
5.66338
.000
.951
.107
–63.9963
–18.5945
–30.7760
–30.7511
12.9448
2.4693
4 1
2
3
–33.22033*
11.32852
14.15337
5.66338
5.37275
5.66338
.000
.201
.107
–49.8430
–4.4411
–2.4693
–16.5977
27.0981
30.7760
12 1 2
3
4
50.13669*
58.07482*
38.27371*
5.10926
5.10926
5.10926
.000
.000
.000
35.5190
43.4571
23.6560
64.7544
72.6925
52.8914
2 1
3
4
–50.13669*
7.93813
–11.86298
5.10926
5.10926
5.10926
.000
.431
.134
–64.7544
–6.6796
–26.4807
–35.5190
22.5558
2.7547
3 1
2
4
–58.07482*
–7.93813
–19.80111*
5.10926
5.10926
5.10926
.000
.431
.007
–72.6925
–22.5558
–34.4188
–43.4571
6.6796
–5.1834
4 1
2
3
–38.27371*
11.86298
19.80111*
5.10926
5.10926
5.10926
.000
.134
.007
–52.8914
–2.7547
5.1834
–23.6560
26.4807
34.4188
*. The mean difference is significant at .05.
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superior to that of the tested bone substitutes. Among 
the replacements, the only statistically significant 
differences were found between the groups with HA 
and GenMix® at 12 weeks, with p = 0.007 (Table 3).
CONCLUSIONS
At both times analyzed, autogenous bone graft 
showed a mean percentage of new bone formation far 
superior to that of the tested bone substitutes.
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